Fierce Pharma
SEPTEMBER 13, 2024
It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s Tecentriq Hybreza after manufacturing delays derailed the company's initia | The under-the-skin formulation trims administration time down to seven minutes compared to the 30 to 60 minutes needed for intravenous Tecentriq.
MedCity News
SEPTEMBER 13, 2024
Apple’s new Loud Sound Reduction capability scans the environment 46,000 times a second for sudden peaks in sound, reducing them to a safe level. The post The Apple AirPods Pro Have a New Hearing Feature, Yet the Biggest Impact May be to Protect Us All From Noise appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
SEPTEMBER 13, 2024
When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | The day after Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.S. nod for its under-the-skin formulation of mega-blockbuster multiple sclerosis drug Ocrevus. The approval gives patients a more convenient injected way to receive Ocrevus as opposed to the infused formulation.
Pharmaceutical Technology
SEPTEMBER 13, 2024
R&D frameworks are in place for the next pandemic-causing pathogen, but ways to derisk development are unclear.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
SEPTEMBER 13, 2024
Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the medicine’s worth in patients whose cancer has spread to the b | To bolster Enhertu's case in HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo have rolled out positive data for the antibody-drug conjugate in patients who have brain metastases.
MedCity News
SEPTEMBER 13, 2024
This week, longtime healthcare veterans Amy Abernethy and Brad Hirsch teamed up to launch Highlander Health — a Dallas-based startup focused on accelerating clinical evidence generation. The post Why Former FDA & Verily Exec Amy Abernethy Is Launching a New Venture appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
SEPTEMBER 13, 2024
Continuous Glucose Monitoring tools are revolutionizing the way diabetes is managed, offering unparalleled benefits for both healthcare providers and patients. By providing continuous, accurate data, CGM is especially useful for remote monitoring, enabling timely interventions and leading to better user health. The post Improved Access to CGM Data Empowers Providers and Patients to More Effectively Partner on Diabetes Management appeared first on MedCity News.
Fierce Pharma
SEPTEMBER 13, 2024
In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final analysis of a phase 3 trial. | In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final analysis of a phase 3 trial. Another study showed that Pharma&’s attempt to enhance its Rubraca with Bristol Myers Squibb’s Opdivo seriously backfired.
MedCity News
SEPTEMBER 13, 2024
As we confront the sobering statistics and growing impact of colorectal cancer, it’s clear that more education about the various options for testing is needed to increase screening rates across the U.S. The post A Closer Look at FIT Tests – A Primer on the Various Options for Colorectal Cancer Screening appeared first on MedCity News.
Fierce Pharma
SEPTEMBER 13, 2024
As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could raise additional doubts around the first-in-class AKT inhibitor. | AstraZeneca is detailing Truqap's pivotal trial flop in triple-negative breast cancer, a result that could raise additional doubts around the first-in-class AKT inhibitor.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
SEPTEMBER 13, 2024
Through a new partnership, students at schools within Cartwheel’s network in need of higher acuity care can access treatment through Charlie Health. The post Charlie Health Partners with Cartwheel to Address the Student Mental Health Crisis appeared first on MedCity News.
Fierce Pharma
SEPTEMBER 13, 2024
Even for Merck’s oncology powerhouse Keytruda, the emerging role of immunotherapies in gynecological cancer treatment represents a bit of a mixed bag. | The company unveiled new data from its KEYNOTE-A18 study in late stage cervical cancer and its failed KEYNOTE-B21 trial testing Keytruda as an adjuvant therapy in newly diagnosed endometrial cancer.
pharmaphorum
SEPTEMBER 13, 2024
It's known that excessive use of earbuds at high volumes can cause hearing loss, so somewhat ironic that the FDA has just authorised software that can turn Apple AirPods into hearing aids.The green light is for Hearing Aid Feature (HAF), an app compatible with Apple's AirPods Pro earbuds that amplifies sounds and can be used for people aged 18 and over with perceived mild to moderate hearing impairment.
PharmaVoice
SEPTEMBER 13, 2024
Three of the largest fundraising rounds in 2024 show where investors are willing to place their bets in biotech.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
SEPTEMBER 13, 2024
Eli Lilly has added $1 billion to its investment plan for a new manufacturing facility in Ireland that will be used to produce its Alzheimer's therapy donanemab.The facility at a business park in Raheen, Limerick, was first announced in 2022 and this is the second time that Lilly has opted to double its investment in the site, taking the total above $2 billion and reinforcing the company's close ties to Ireland's pharma manufacturing sector.
MedCity News
SEPTEMBER 13, 2024
Bicara Therapeutics’ IPO raised $315 million raised for Phase 3 testing of a bifunctional antibody drug with potential to become a first-line treatment for head and neck cancers. Zenas BioPharma and MBX Biosciences also went public; all three companies upsized their IPOs. The post 3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders appeared first on MedCity News.
Pharmaceutical Technology
SEPTEMBER 13, 2024
The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer immunotherapy.
pharmaphorum
SEPTEMBER 13, 2024
The PM Society Digital Awards 2024, an annual event in the healthcare marketing industry sponsored by Twist Health, held its 15th ceremony at The Brewery in London on 12th September.
Pharmaceutical Technology
SEPTEMBER 13, 2024
Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination campaign.
PharmaTimes
SEPTEMBER 13, 2024
Innovative immunotherapy drug HTL0039732 shows potential in trials
pharmaphorum
SEPTEMBER 13, 2024
Cellino Biotech has received funding from the US government to develop a scalable biomanufacturing platform for personalised regenerative medicines derived from patients' own stem cells.The $25 million award from the Advanced Research Projects Agency for Health (ARPA-H) will be used to develop Cellino's NEBULA system, which according to the firm's chief technology Matthias Wagner can "effectively print new cells and new tissues for patients using their own DNA.
PharmaTimes
SEPTEMBER 13, 2024
GlobalData emphasises importance of Improved clinical trials
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Quantified
SEPTEMBER 13, 2024
Introduction Sales enablement is transforming, driven by advancements in artificial intelligence (AI). Traditional sales training methods, while foundational, often fall short in delivering the speed, personalization, and realism required in today’s competitive market. AI is revolutionizing key pillars of sales enablement, particularly in onboarding new hires and conducting realistic role-play scenarios.
Pharmacy Times
SEPTEMBER 13, 2024
AI is significantly enhancing the efficiency of identifying and enrolling patients.
PharmaTech
SEPTEMBER 13, 2024
Descon Conveyor Systems is joining Pacteon’s portfolio, and its product will be shown alongside those from Schneider Packaging Equipment and Phoenix Stretch Wrappers.
pharmaphorum
SEPTEMBER 13, 2024
UK biotech F2G has raised $100 million as it prepares to refile its olorofim candidate for invasive fungal infections, which was turned down last year by the FDA.The Manchester-based company said the new cash will help it to complete the late-stage development of olorofim, a novel oral antifungal for invasive aspergillosis and other serious fungal infections, to support the company during the regulatory review process, and prepare for a commercial launch in the US.
Pharmacy Times
SEPTEMBER 13, 2024
In the absence of a common treatment for long COVID, researchers from around the world documented the best currently available therapies.
Rep-Lite
SEPTEMBER 13, 2024
In the medical sales industry, competition is fierce and the demand for innovative healthcare products is high. Having a top-tier sales team isn’t just an asset—it’s a necessity for driving business growth. Without skilled sales professionals, even the best products can struggle to gain traction in a crowded market. So, how do you build a medical sales team that excels?
Pharmacy Times
SEPTEMBER 13, 2024
Data show the value of the pharmacist is clear for patients with type 2 diabetes, as their role can have a significant impact on reductions in hemoglobin A1c.
PharmaTech
SEPTEMBER 13, 2024
The critical APIs that this funding will contribute to are used in the treatment of asthma, diabetes, and anxiety disorders.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
317 
Let's personalize your content